Missed Hepatitis B Shots at Birth: Study Warns of Critical Gaps in Infant Protection

A recent study has highlighted significant risks associated with missed hepatitis B vaccine doses at birth, warning that delayed or omitted vaccination increases the likelihood of incomplete immunization and long-term health complications in children.

The research, published in MedPage Today, analyzed hepatitis B vaccination patterns and found that infants who do not receive the birth dose of the hepatitis B vaccine are at heightened risk for under-immunization by 18 and 24 months of age. This early gap in vaccination can disrupt the full vaccine series, leaving children vulnerable to hepatitis B virus (HBV) infection during critical developmental years.

According to the study, timely administration of the hepatitis B birth dose is a key factor in ensuring completion of the recommended three-dose vaccine series. When this initial dose is missed, infants are more likely to fall behind on subsequent vaccinations, which are typically administered at 1–2 months and 6 months of age. The study emphasized that early intervention is critical to establishing immunity and preventing chronic infection.

Supporting evidence from additional research reinforces these findings. A separate analysis released in December 2025 modeled the public health impact of delaying the hepatitis B birth dose in the United States. Based on 2024 U.S. Birth data, the study projected that even a two-month delay in administering the birth dose to infants born to hepatitis B-negative mothers could result in at least 1,400 preventable pediatric hepatitis B infections annually, along with 300 excess cases of liver cancer, 480 preventable deaths and over $222 million in avoidable healthcare costs.

The same analysis warned that extending the delay to 12 years would dramatically increase these outcomes, projecting at least 2,700 preventable infections and $313 million in excess healthcare costs per year. Researchers involved in the study, including experts from Oregon Health & Science University, Emory University, and Cornell University, stressed that timely birth dose vaccination is a critical tool for preventing lifelong hepatitis B infection and its severe complications, including cirrhosis and hepatocellular carcinoma.

Public health guidelines continue to recommend universal hepatitis B vaccination at birth as a cornerstone of pediatric infectious disease prevention. The vaccine has been shown to reduce pediatric HBV infections by more than 99% since its widespread implementation, according to data cited in peer-reviewed literature. Health authorities emphasize that the birth dose provides immediate protection, particularly for infants born to mothers with unknown or undiagnosed hepatitis B status, and serves as a critical safety net in preventing perinatal transmission.

Despite high overall vaccination rates, gaps persist. Earlier data cited in the MedPage Today report indicated that while 81.2% of children received a hepatitis B birth dose, only 87.1% were fully vaccinated by age 18 months. This discrepancy underscores the importance of the birth dose as a predictor of vaccine series completion. Infants who miss this initial dose are significantly less likely to receive the full series on schedule, increasing their risk of infection during early childhood.

Experts caution that delayed or missed hepatitis B vaccination at birth not only leaves individuals susceptible to acute infection but also raises the likelihood of chronic hepatitis B, which can lead to progressive liver disease, liver cancer, and premature death decades later. Because hepatitis B often remains asymptomatic for years, early prevention through vaccination is essential to avoid long-term morbidity and mortality.

Healthcare providers are encouraged to prioritize hepatitis B birth dose administration in hospital settings and to implement tracking systems to ensure follow-up doses are completed. Public health campaigns continue to focus on improving awareness among expectant parents and perinatal care teams about the safety, effectiveness, and necessity of the hepatitis B vaccine at birth.